ERIS Lifesciences Ltd: Stock Analysis & Fundamentals

Updated this week

ERIS Lifesciences Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 41.9. ROE: 12.9%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

🌐FII stake decreased 0.8% this quarter

Key Numbers

Current Price

₹1,341

Dividend Yield

0.55%

Market Cap

18.6K Cr

Valuation

N/A

Other Top Pharma - Formulators Stocks Beating Nifty 500

Sun Pharmaceutical Industries Ltd

Strong • 4w streak

+15.9%

Torrent Pharmaceuticals Ltd

Average • 12w streak

+23.4%

Dr Reddys Laboratories Ltd

Zydus Lifesciences Ltd

Weak

+10.0%

← Back to Pharma - Formulators Dashboard

Frequently Asked Questions: ERIS Lifesciences Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were ERIS Lifesciences Ltd's latest quarterly results?

ERIS Lifesciences Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: +25.3%
Revenue Growth YoY: +11.0%
Operating Margin: 35.0%

What is ERIS Lifesciences Ltd's current PE ratio?

ERIS Lifesciences Ltd's current PE ratio is 41.9x.

Current PE: 41.9x
Market Cap: 18.6K Cr
Dividend Yield: 0.55%

What is ERIS Lifesciences Ltd's price-to-book ratio?

ERIS Lifesciences Ltd's price-to-book ratio is 5.9x.

Price-to-Book (P/B): 5.9x
Book Value per Share: ₹227
Current Price: ₹1341

Is ERIS Lifesciences Ltd a fundamentally strong company?

ERIS Lifesciences Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 12.0%

Is ERIS Lifesciences Ltd debt free?

ERIS Lifesciences Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹2,000 Cr

What is ERIS Lifesciences Ltd's return on equity (ROE) and ROCE?

ERIS Lifesciences Ltd's return ratios over recent years

FY2023: ROCE 17.0%
FY2024: ROCE 11.0%
FY2025: ROCE 12.0%

Is ERIS Lifesciences Ltd's cash flow positive?

ERIS Lifesciences Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹1,000 Cr
Free Cash Flow (FCF): ₹987 Cr
CFO/PAT Ratio: 284% (strong cash conversion)

What is ERIS Lifesciences Ltd's dividend yield?

ERIS Lifesciences Ltd's current dividend yield is 0.55%.

Dividend Yield: 0.55%
Current Price: ₹1341

Who holds ERIS Lifesciences Ltd shares — promoters, FII, DII?

ERIS Lifesciences Ltd's shareholding pattern (Dec 2025)

Promoters: 54.9%
FII (Foreign): 6.8%
DII (Domestic): 20.3%
Public: 18.0%

Is promoter holding increasing or decreasing in ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 54.9% (Dec 2025)
Previous Quarter: 54.9% (Sep 2025)
Change: 0.00% (stable)

Is ERIS Lifesciences Ltd a new momentum entry or an established outperformer?

ERIS Lifesciences Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is ERIS Lifesciences Ltd worth studying for long term investment?

Based on quantitative research signals, here is why ERIS Lifesciences Ltd may be worth studying

Cash flow is positive — CFO ₹1,000 Cr

What is the investment thesis for ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd investment thesis summary:

What is the future outlook for ERIS Lifesciences Ltd?

ERIS Lifesciences Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.